Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, randomized, placebo-controlled, ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HL161BKN following single intravenous and subcutaneous doses in healthy subjects

Next Previous
X
Search
Trial Profile

A Phase 1, randomized, placebo-controlled, ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HL161BKN following single intravenous and subcutaneous doses in healthy subjects

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Batoclimab (Primary) ; Batoclimab (Primary)
  • Indications Autoimmune disorders; Graves ophthalmopathy; Myasthenia gravis
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 09 May 2019 According to a Roivant Sciences media release, the first detailed findings from this study will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting.
    • 07 Jan 2019 According to a Roivant Sciences media release, updated data form this study will be presented at the J.P. Morgan Healthcare Conference.
    • 10 Jul 2018 According to a Roivant Sciences media release, preliminary clinical data from this study will be presented today at the First Annual Pipeline Day of the Company.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top